接受新辅助化疗的三阴性乳腺癌患者影像学与病理学完全缓解不一致性研究
本回顾性队列研究纳入2013年1月至2022年4月单中心诊断的186例三阴性乳腺癌患者,评估新辅助化疗后MRI和US的影像学完全缓解(rCR)与病理学完全缓解(pCR)的一致性。未接受免疫治疗者pCR与MRI中度一致(κ=0.60),与US弱一致(κ=0.42);接受免疫治疗者一致性降低(MRI κ=0.39,US κ=0.05),且MRI无rCR者中免疫治疗与pCR强相关(p=0.009),NPV在免疫治疗组为50% vs 无免疫治疗组84%。
要点
- 三阴性乳腺癌新辅助化疗后,未接受免疫治疗者MRI与pCR中度一致(κ=0.60),US弱一致(κ=0.42)。
- 接受免疫治疗者MRI与pCR一致性降低(κ=0.39),US与pCR无一致性(κ=0.05)。
- MRI无rCR者中,免疫治疗组NPV为50% vs 无免疫治疗组84%,提示MRI可能高估残留肿瘤。
核心结论
- 接受免疫治疗的三阴性乳腺癌患者新辅助化疗后MRI的NPV显著降低,提示MRI可能高估残留肿瘤;需进一步研究免疫治疗所致炎症改变以解释该不一致性。
研究设计与样本
- 单中心回顾性队列研究,纳入2013年1月至2022年4月诊断的186例三阴性乳腺癌患者,均在新辅助化疗前后行动态增强MRI或乳腺US,以手术切除病理分期为参考标准。
诊断标准与关键数值
- 未接受免疫治疗者pCR与MRI中度一致(κ=0.60),pCR与US弱一致(κ=0.42)。
- 接受免疫治疗者pCR与MRI一致性降低(κ=0.39),pCR与US无一致性(κ=0.05)。
- MRI无rCR者中,免疫治疗组NPV为50% vs 无免疫治疗组84%。
临床应用与阅片要点
- 原文结论提示,接受新辅助化疗联合免疫治疗的三阴性乳腺癌患者,MRI可能高估残留肿瘤。
- 作者指出需进一步研究免疫治疗所致炎症改变以解释影像与病理不一致性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Pathologic complete response (pCR) following neoadjuvant chemotherapy (NAC) is a key marker of long-term outcomes in patients with triple-negative breast cancer (TNBC). Accurate radiologic assessments of response to NAC using breast MRI and US play an important role in guiding treatment decisions, though the effects of immunotherapy (IO) on radiologic assessments are not well characterized. We examined the discordance between radiologic complete response (rCR) and pCR in patients with TNBC following NAC with or without IO.
MATERIALS AND METHODS: This is a retrospective cohort study of patients from a single institution diagnosed between January 2013 and April 2022 with TNBC who underwent dynamic contrast-enhanced MRI or US breast imaging before and after NAC. Radiology reports of post-NAC MRI and US scans were examined for presence of rCR, and these findings were correlated with pathologic stage on surgical resection. Concordance between rCR and pCR was measured using Cohen's kappa (κ) statistic. Association between the receipt of IO and pCR among patients without rCR on post-NAC MRI/US was measured using Fischer's exact test.
RESULTS: We identified 186 patients from the cohort meeting inclusion criteria. 166 (89%) patients had high tumor grade, 174 (94%) patients had ductal histologic subtype, 81 (44%) patients had pCR, and 34 (18%) patients received IO. Among patients not receiving IO, pCR and MRI were moderately concordant (κ = 0.60), and pCR and US were weakly concordant (κ = 0.42). Discordance was pronounced in those receiving IO, with reduced concordance between pCR and MRI (κ = 0.39), and no concordance between pCR and US (κ = 0.05). Among patients with no rCR on MRI, there was a strong association between IO and pCR (p = 0.009) with a poor negative predictive value (NPV) of 50% in patients receiving NAC with IO compared to an NPV of 84% in patients receiving NAC without IO.
CONCLUSION: We present data that demonstrate a statistically significant reduction in the NPV of post-NAC MRI in patients with TNBC receiving IO. These findings suggest that MRI following neoadjuvant chemoimmunotherapy may overcall residual tumor in TNBC. Further research is necessary to better characterize any underlying immunotherapy induced inflammatory changes that may explain this discordance.
引用
- Dhungana A, Guo W, Huo D, et al. Discordance of Radiologic and Pathologic Complete Response in Patients with Triple-negative Breast Cancer Undergoing Neoadjuvant Chemotherapy. Acad Radiol. 2025. PMID: 41469290. doi:10.1016/j.acra.2025.12.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。